We use essential cookies to run this site and cookie-free visitor statistics, which you can switch off. Marketing cookies only with your consent. Cookie policy

EssentialAlways on

Keep the site secure and working, and remember your cookie choice.

Visitor statistics

Cookie-free counts of which pages are used and how fast they load, so we can improve them. On unless you switch it off.

Marketing

Measure our campaigns on other sites, such as LinkedIn. Off until you allow it.

/ Whole blood inline leukoreduction filter

CellNet™ PR

A leukocyte and platelet removal filter for whole blood.

Built for red cell and plasma production. One inline pass takes out the leukocytes and platelets, so every unit starts cleaner, with no extra step in the blood center.

Why platelets?

/ Recognized in 2026

  • Edison Awards Silver winnerEnergy & Climate Resiliency
  • R&D 100 Award WinnerProcess / Prototyping
CellNet™ PR

Performance

What it takes out. What it keeps.

  • Taken out

    Leukocytes

    <0.3 × 10⁶ residual per unit

    The cells behind febrile reactions, HLA alloimmunization and CMV transmission.

  • Taken out

    Platelets

    >98% removed at filtration

    Selectively captured by the media and removed at filtration, before the unit goes into storage.

  • Kept

    Red cells

    91–95% recovery

    More of every donation becomes a usable unit, with less left behind in the filter.

  • Kept

    Plasma

    Platelet-poor from the set

    Before centrifugation, with no extra step in the blood center.

CellNet™ PR on fresh human whole blood. Presented at the 39th ISBT International Congress, 2026. Full methods and results are in the technical brochure.

01

In your set

One filter, inline, between the primary bag and the satellite bags.

The unit is filtered once by gravity, then separated into leukoreduced, platelet-reduced red cells and plasma, or used as whole blood. No change to the components you already make.

Line drawing of a whole blood collection set: donor line and primary bag (1), CellNet™ PR inline filter (2), then the satellite bags for red cells and plasma (3).
  1. 1CollectWhole blood into the primary bag.
  2. 2FilterOnce, by gravity, through CellNet™ PR.
  3. 3ProcessFor separation into red cells and plasma, or as whole blood.

Example set configuration, for illustration. CellNet™ PR can be built into any inline whole blood collection system. Ask about your set

02

Applications

One filtration step at the whole blood stage, carried from separation through storage to emergency care.

01Cell separation

In the blood center, when whole blood becomes components.

  • Red cells · Plasma

    Component production

    Whole blood is filtered once, inline, before centrifugation. Red cells and plasma separate already leukoreduced and platelet-poor, with no extra step.

    How it sits in the set

02Storage and products

What the components are like over their shelf life.

  • Red cells

    Red cell concentrates

    Stored for up to 42 days without the platelets that would otherwise activate and shed microparticles and cytokines over the shelf life.

    In the research
  • Plasma

    Frozen plasma

    Platelet-poor before it is frozen, with fewer platelets carried into the freezer, where they fragment.

    In the research
  • Plasma

    Cryoprecipitate

    Made from platelet-depleted plasma, so its content is defined by the plasma proteins rather than by variable platelet debris.

    In the research

03Prehospital and emergency care

Red cells and plasma, ready where they’re needed.

Leukocyte- and platelet-depleted whole blood

Red cells and plasma in one unit, for prehospital and emergency care

Red cells and plasma, the combination UK prehospital teams rely on for major hemorrhage, in one leukocyte- and platelet-depleted unit: Red Cells and Plasma, Leucocyte Depleted (RCP).* Not platelet-sparing whole blood. Platelets can follow in hospital, when they’re needed.

Ask about red cells and plasma

Why it’s made this way

  • Red cells and plasma firstOxygen delivery and clotting factors first. In the SWiFT trial, adding platelets via whole blood before hospital showed no benefit.†
  • One bagOne unit to carry, check and transfuse instead of two.
  • Platelets out>98% removed. Platelet sCD40L and lysophospholipids are reported second hits for TRALI in patients already primed by trauma, infection or surgery.‡
  • Leukocytes outThe cells behind febrile reactions, HLA alloimmunization and CMV transmission,§ and a proposed driver of immunomodulation.‖
Sources +
  1. * McCullagh J, Proudlove N, Tucker H, et al. Making every drop count: reducing wastage of a novel blood component for transfusion of trauma patients. BMJ Open Qual 2021;10(3):e001396. pmc.ncbi.nlm.nih.gov/articles/PMC8268902
  2. † Smith JE, Cardigan R, Sanderson E, et al. (SWiFT Trial Group). Prehospital whole blood in traumatic hemorrhage: a randomized controlled trial. N Engl J Med 2026. doi:10.1056/NEJMoa2516043 pubmed.ncbi.nlm.nih.gov/41841706
  3. ‡ Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006;108:2455–62. pmc.ncbi.nlm.nih.gov/articles/PMC1895564
  4. ‡ Silliman CC, Burke T, Kelher MR. The accumulation of lipids and proteins during red blood cell storage: the roles of leucoreduction and experimental filtration. Blood Transfus 2017;15(2):131–6. doi:10.2450/2017.0314-16 pmc.ncbi.nlm.nih.gov/articles/PMC5336334
  5. § British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines on the clinical use of leucocyte-depleted blood components. Transfus Med 1998;8:59–71. b-s-h.org.uk/media/16279/leucocyte-dpleted-blood-1998.pdf
  6. ‖ Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007;21(6):327–48. doi:10.1016/j.blre.2007.07.003 read.qxmd.com/doi/10.1016/j.blre.2007.07.003

Beyond whole blood

Have a different separation problem?

We develop the media for it and prove it on our pilot line.

Talk to our R&D team
03

Global collection standards

Engineered to perform for every collection standard, globally.

Collection standards vary by market. Your filter shouldn’t. Two product lines, PR 250 and PR 500, share one media and deliver the same leukoreduction below the European limit at every volume from 200 to 500 mL. One platform for every set you build and every market you supply, so blood reaches the patients who need it, wherever it’s collected.

  • Engineered at the fiber

    Supercritical CO₂ builds the media’s affinity through the depth of every fiber, so each unit meets the same material.

  • Sized to the unit

    Two housings, each matched to its volume range, so the media works within its design window at every unit size.

  • Below the EDQM limit, worldwide

    Residual leukocytes under 1 × 10⁶ per unit at every volume tested, on both sizes.

PR 250

200–250 mL

  • 200 mLJapan · China
  • 250 mLTaiwan · Vietnam

PR 500

300–500 mL

  • 300 mLSouth Korea
  • 350 mLMalaysia
  • 400 mLChina · Japan · South Korea
  • 450 mLEurope · Turkey · Malaysia
  • 500 mLTaiwan · United States

Unit volumes ±10%.

StandardResidual leukocytes, requiredCellNet™ PR
Council of Europe · EDQM Guide<1 × 10⁶ per unitMet
AABB · US FDA<5 × 10⁶ per unitMet
Japan · Japanese Red Cross<1 × 10⁶ per bagMet
China · GB 18469-2012≤2.5 / 3.8 / 5.0 × 10⁶ (200 / 300 / 400 mL units)Met
Taiwan · Taiwan Blood Services Foundation<5 × 10⁶ per unitMet
Performance for each size in the specifications
04

Why platelets

After leukoreduction, platelets are the main cells left in a red cell unit.

In storage they activate and shed microparticles and cytokines that no later step can remove.1,2,3 Taking them out at filtration, before storage, prevents it at the source.4 The plasma starts platelet-poor as well.

Read the research
Sources +
  1. Glenister KM et al. Level of platelet-derived cytokines in leukoreduced red blood cells is influenced by the processing method and type of leukoreduction filter. Transfusion 2010;50:185–9.
  2. Khan SY et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in TRALI. Blood 2006;108:2455–62.
  3. Rubin O et al. Microparticles in stored red blood cells: submicron clotting bombs? Blood Transfus 2010;8 Suppl 3:s31–8.
  4. Sugawara A, Nollet KE, Yajima K, Saito S, Ohto H. Preventing platelet-derived microparticle formation, and possible side effects, with prestorage leukofiltration of whole blood. Arch Pathol Lab Med 2010;134:771–5.
05

Specifications

Full specifications

Performance, use, materials and manufacturing data for PR 250 and PR 500, with drawings, biocompatibility and the ISBT 2026 results. Sent by our team on request.

  • Performance
  • Use
  • Materials
  • Manufacturing
06

The media inside

Media engineered with purpose, pushing the limits of traditional methods.

Scanning electron micrograph at ×100,000 of an unmodified filter fiber: a smooth surface
Scanning electron micrograph at ×100,000 of the same fiber after supercritical CO₂ modification: a textured surface
The fiber surface at ×100,000, before and after our supercritical CO₂ modification. Drag the handle to compare.

We modify the fiber with supercritical CO₂, which carries the chemistry through its full depth. No solvent baths, no rinsing, no process wastewater, and the CO₂ is recycled.

0 L
process water
0
organic solvents
CO2
recycled in the process
07

For set makers

Your blood bag system, equipped with CellNet™ technology.

  1. 01Evaluate

    Evaluation units

    Units under NDA, with the technical brochure, so your engineers can test CellNet™ PR in your own set before any commitment.

    Request evaluation units
  2. 02Qualify

    A technical file, ready to use

    Biocompatibility, extractables, lot records and change control for your submission, plus engineering time for your validation.

    Ask for the file contents
  3. 03Supply

    Long-term supply

    Agreements with committed capacity, scaled to your forecast, with full lot traceability.

    Talk about supply
08

Resources

  • PDFTechnical brochureSpecifications, drawings, materials, biocompatibility and the ISBT 2026 results.
  • ArticleWhy remove platelets?What platelets do in a stored red cell unit, and the research behind it. Read : Why remove platelets?
  • Data packSustainability dataSupplier carbon, water and materials data for Scope 3 and supplier reviews. Get : Sustainability data
  • CertificateISO 13485Quality management system certificate for our Yilan site. Request : ISO 13485

Sangtech develops and manufactures CellNet™ filter media and semi-finished filters for medical device manufacturers and research facilities. CellNet™ PR is not a medical device and cannot perform a medical function on its own. This page provides general product information. Performance figures are from Sangtech internal validation on fresh and overnight-held (OVN) whole blood; full methods, sample sizes and results are in the technical brochure. Availability and configuration vary by market; please contact us.

Evaluate CellNet™ PR in your set.

Tell us about your collection set and volumes. A specialist will be in touch.

Talk to a specialist

Request the technical brochure

Our team will email it to you.

I work at a…
Interested in Optional